Some countries—including the U.S. and the U.K.—are securing vast quantities of new coronavirus vaccine candidates in a phenomenon being dubbed 'vaccine nationalism.'
-- a government-funded initiative to turbocharge vaccine development and secure vaccine doses for the U.S. population. In total, almost $10 billion has been allocated by Congress for hundreds of millions of doses to be made available to U.S. citizens.
U.S. President Donald Trump delivers a speech during a visit to the Fujifilm Diosynth Biotechnologies' Innovation Center, a pharmaceutical manufacturing plant where components for a potential coronavirus vaccine candidate are being developed, in Morrrisville, N.C., July 27, 2020.Some have compared the coronavirus vaccine buyouts to the 2009 swine flu pandemic, when wealthier countries bought up of most of the vaccine doses. The U.S.
Even countries that do secure large doses of vaccine candidates, the risk remains that the vaccine they bought simply doesn't work well enough. Some countries could be playing a potentially dangerous game by gambling on a small number of vaccines.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Vaccine nationalism: Experts warn countries against taking 'me-first' approachAs the race for a novel coronavirus vaccine continues, there's growing concern from scientists and economic experts that wealthy nations are prioritizing getting doses for their own citizens at the cost of poorer nations and thus failing to control the global pandemic. In the midst of this debate
Weiterlesen »
Calendar of confusion: From February to August, Trump's mixed messages on masksTrump admin's conflicting messaging about mask-wearing over the last 4 to 5 months has created widespread confusion, hampered the country's response to the coronavirus pandemic and even led to preventable deaths, multiple health experts say.
Weiterlesen »
Goldman raises economic growth outlook as it sees a vaccine approval this yearThe firm sees 'at least one' vaccine approved by the end of 2020 and hitting the market for widespread distribution by the second quarter of 2012.
Weiterlesen »